Summary
Nine patients with myeloid blast crisis of Philadelphia chromosome-positive chronic myelocytic leukemia received 1–3 courses of intensive induction chemotherapy with DAT (daunomycin, cytosin-arabinoside and 6-thioguanin) or DAV (daunomycin, cytosin-arabinoside and VP-16). Eight patients responded with clearing of blasts from peripheral blood giving a response rate of 89%. However, bone marrow aplasia with less than 5% blasts was seen in only 2 patients. These 2 patients subsequently received an allogeneic bone marrow transplant and achieved complete remissions of 3 and 6 month duration. All patients died due to progression of blast crisis. Median survival of the group was 164 days. These results were compared to a historical control group of 31 patients with myeloid blast crisis treated with vincristine and prednisone. Despite a significantly better response rate with DAV or DAT (8 of 9 versus 9 of 31, p=0.01) survival was not significantly different than that of the control group.
This is a preview of subscription content, log in via an institution to check access.
References
Anger B, Carbonell F, Braunger I, Heinze B, Gutensohn W, Thiel E, Heimpel H (1988) Blast crisis of Philadelphia chromosome-positive chronic myelocytic leukemia (CML). Treatment results of 69 patients. Blut 57: 131–137
Beard M, Gauci C, Sikora E, Kirk B, Hamilton Fairly G, Wrigley P (1976) Blast crisis of chronic myeloid leukemias: the effect of intensive chemotherapy. Scand J Haematol 16: 258–262
Champlin RE, Goldman JM, Gale RP (1988) Bone marrow transplantation in chronic myelogenous leukemia. Semin Hematol 25: 74–80
Coleman M, Silver RT, Pajak TF, Cavalli F, Rai KR, Kostinas JE, Glidewell O, Holland JF (1980) Combination chemotherapy for terminal phase chronic granulocytic leukemia: cancer and leukemia group B studies. Blood 55: 29–36
De Witte T, Raymakers R, de Pauw B, Haanen C (1985) Repetitive cycles of cytoreductive therapy followed by stem cell autografting for nonlymphoblastic transformation of chronic granulocytic leukaemia. Scand J Hameatol 35: 558–563
Haines ME, Goldman JH, Worsley AM, McCarthy DM, Wyatt SE, Dowding C, Kearney L, Thing KH, Wareham NJ, Pollock A, Galvin MC, Samson D, Geary SG, Catovsky D, Galton DA (1984) Chemotherapy and autografting for chronic granulocytic leukaemia in transformation: probable prolongation of survival for some patients. Br J Haematol 58: 711–721
Iacoboni SJ, Plunkett WK, Kantarjian H (1986) High dose cytosin-arabinoside: Treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J Clin Oncol 4: 1079–1088
Marks SM, Baltimore D, McCaffrey R (1978) Terminal transferase as a predictor of initial responsivness to vincristine and prednisone in blastic myelogenous leukemia: a co-operative study. N Engl J Med 298: 812–814
Preisler HD, Raza A, Higby D, Kirshner J, Woll J, Bennett J, Winton L, Weiner R, Richman C, Golomb H, Goldberg J (1984) Treatment of myeloid blastic crisis of chronic myelogenous leukemia. Cancer Treat Rep 68: 1351–1355
Rosenthal S, Canellos G, Whang-Peng J, Gradwick A (1977) Blast crisis of chronic granulocytic leukemia. Morphologic variants and therapeutic implications. Am J Med 63: 542–547
Schiffer CA, DeBellis R, Kasdorf H, Wiernik PH (1982) Treatment of the blast crisis of chronic myelogenous leukemia with 5-azacytidine and VP-16-213. Cancer Treat Rep 66: 267–271
Spiers ASD, Goldman JM, Catovsky D et al (1977) Multipledrug chemotherapy for acute leukemia. The TRAMPCOL regimen: Results in 86 patients. Cancer 40: 40–49
Thomas ED, Clift RA, Fefer A, Appelbaum FR, Beatty P, Bensinger WI, Buckner CD, Cheever HA, Deeg HJ, Doney K, Flourney N, Greenberg P, Hansen JA, Martin P, McGuffin R, Ramberg R, Sanders JE, Singer J, Stewart P, Storb R, Sullivan K, Weiden PL, Witherspoon R (1986) Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Int Med 104: 155–163
Winton EF, Miller D, Vogler WR (1981) Intensive chemotherapy with daunorubicin, 5-azacytidine, 6-thioguanine and cytarabine (DATA) for the blastic transformation of chronic granulocytic leukemia. Cancer Treat Rep 64: 389–392
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Anger, B., Heimpel, H. Daunomycin, cytosin-arabinoside and VP-16 (DAV) for myeloid blast crisis of CML. Blut 58, 299–301 (1989). https://doi.org/10.1007/BF00320171
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00320171